ORY-1001 – 5 mg

Brand:
Cayman
CAS:
1431326-61-2
Storage:
-20
UN-No:
De Minimis - 3077 / 9

Lysine-specific demethylase 1 (LSD1) demethylates H3K4 and H3K9, resulting in transcriptional repression.{14724} It also controls the tumor suppressor activity of p53 by demethylating a specific p53 lysine residue (LYS370).{15022} ORY-1001 is an orally available, selective inhibitor of LSD1 (IC50 < 20 nM).{31138,31139} It targets acute myeloid leukemia (AML) stem cells and significantly reduces tumor cell load while increasing survival time in mouse models of AML.{31138,31139} ORY-1001 is in clinical trials for cancer treatment.{31139}  

 

Available on backorder

SKU: - Category:

Description

An orally available, selective inhibitor of LSD1 (IC50 < 20 nM); targets AML stem cells


Formal name: rel-N1-[(1R,2S)-2-phenylcyclopropyl]-1,4-cyclohexanediamine, dihydrochloride

Synonyms:  RG-6016

Molecular weight: 303.3

CAS: 1431326-61-2

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors|Demethylases||Research Area|Epigenetics, Transcription, & Translation|Erasers|Histone Demethylation